PIPELINE PRODUCTS PENDING APPROVAL OF HADASIT TRANSACTION
Type
II diabetes (also known as "adult onset diabetes" and "non-insulin
dependent diabetes") is a metabolic disease that increases in incidence
and prevalence with age. Type II diabetes sufferers become resistant
to insulin produced by the pancreas; as glucose is not properly
metabolized, serum glucose levels rise, resulting in serious vascular,
renal, neurological and ophthalmologic complications. It is estimated
that in the USA alone, 20 million Americans suffer from Type II
diabetes. 'First-line' treatment for Type II diabetes is diet, weight
control and physical activity. If blood glucose levels remain high,
medication (e.g., Metformin) is administered. Insulin may be
administered should medication fail to lower blood glucose levels.
Diabetes is one of the most common non-communicable diseases globally. It is the 4th or 5th leading cause of death in most developed countries. There is also substantial evidence that it is epidemic in many developing nations. Diabetes will be one of the most challenging health problems in the 21st century. Complications from diabetes such as coronary artery and peripheral vascular disease, stroke, diabetic neuropathy, amputations, renal failure, and blindness result in increased disability, reduced life expectancy, and enormous health cost. The monitoring, control, and treatment of diabetes and its complications are a major focus of biomedical research and development efforts. The biomedical industry is focused on metabolic disease as it represents one of the greatest areas of unmet need in medicine.
Immuron has been collaborating with experts at Hadassah Medical Center, Jerusalem, to utilize anti-insulin antibodies and other proteins, with appropriate adjuvants, to induce antigen specific regulatory T cells that suppress the immune response associated with the diabetes process. In April 2009, Immuron had announced a pending deal to acquire the technology from Hadasah.
Animal data show reduced blood glucose levels and improved oral glucose tolerance testing. By addressing Metabolic Syndrome (and in particular NASH-"fatty liver") and Type II diabetes as an immune mediated disease we intend to bring new, more convenient and safer treatment options to patients worldwide.
Our research efforts and clinical trial results will furthermore allow Immuron to address a number of other immune mediated components of the Metabolic Syndrome.
Diabetes is one of the most common non-communicable diseases globally. It is the 4th or 5th leading cause of death in most developed countries. There is also substantial evidence that it is epidemic in many developing nations. Diabetes will be one of the most challenging health problems in the 21st century. Complications from diabetes such as coronary artery and peripheral vascular disease, stroke, diabetic neuropathy, amputations, renal failure, and blindness result in increased disability, reduced life expectancy, and enormous health cost. The monitoring, control, and treatment of diabetes and its complications are a major focus of biomedical research and development efforts. The biomedical industry is focused on metabolic disease as it represents one of the greatest areas of unmet need in medicine.
Immuron has been collaborating with experts at Hadassah Medical Center, Jerusalem, to utilize anti-insulin antibodies and other proteins, with appropriate adjuvants, to induce antigen specific regulatory T cells that suppress the immune response associated with the diabetes process. In April 2009, Immuron had announced a pending deal to acquire the technology from Hadasah.
Animal data show reduced blood glucose levels and improved oral glucose tolerance testing. By addressing Metabolic Syndrome (and in particular NASH-"fatty liver") and Type II diabetes as an immune mediated disease we intend to bring new, more convenient and safer treatment options to patients worldwide.
Our research efforts and clinical trial results will furthermore allow Immuron to address a number of other immune mediated components of the Metabolic Syndrome.